SOURCE: Population Diagnostics, Inc.

June 11, 2007 10:15 ET

Population Diagnostics, Inc. to Discuss Autism Diagnostic Breakthroughs at the 2007 Life Sciences Industry Summit

MELVILLE, NY--(Marketwire - June 11, 2007) - Population Diagnostics, Inc. announced today that Jim Chinitz, the company's CEO, will present a corporate overview at the 2007 Life Sciences Industry Summit to be held on June 14th at the Huntington Hilton in Melville, NY. Mr. Chinitz is an invited speaker by the sponsors, the Long Island Life Sciences Initiative (LILSI) and the New York State Center for Biotechnology. The overview will emphasize their novel approach to revealing causative biomarkers for human disease, which are the key ingredients to developing DNA-based diagnostics and personalized medicine tests with the highest level of clinical value. The presentation will include information about its prototype platform, which has revealed causative biomarkers for Autism, paving the way for the development of a screening test.

About Population Diagnostics, Inc.

The company (www.populationdiagnostics.com) has developed a proprietary platform for the rapid and systematic discovery of "causative" genetic mutations linked to complex disease. Building on its novel technology, Population Diagnostics is focused on the development and the direct marketing of diagnostic tests in medical markets with unmet needs. Tests for Autism, Alzheimer's, Parkinson's, Diabetes, Risk of Stroke and others represent the company's pipeline. Additionally, the company is engaged with pharmaceutical companies interested in revealing causative biomarkers which will be used to selectively identify patients who will benefit the most from a drug, or to exclude those who are most likely to experience a serious adverse effect. "Causative" mutations are the only biomarkers which can be used to develop predictive tests because they represent certainty that the disease is present or it will eventually develop in a patient. In contrast, alternative technologies which represent the status quo only reveal "predisposition" or "risk factor" indicators, which give false hopes to laypeople, cause patients and physicians to make baseless decisions, and therefore are not suitable for developing and marketing diagnostic tests.

Contact Information